Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd

Link copied
Case Copied 15 min read

FEDERAL COURT OF AUSTRALIA

Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd [2024] FCA 1488

File number: NSD 698 of 2024
Judgment of: JACKMAN J
Date of judgment: 17 December 2024
Catchwords: PATENTS – application for an interlocutory injunction by patent holder – where generic recently launched – where patent holder is claiming for infringement – where patent alleged to be invalid – whether balance of convenience favours the grant of an injunction – where there has been substantial delay on the part of the patent holder – where detriment to the patent holder if the injunction is not granted is much more readily quantifiable in damages than the detriment to the generic – application dismissed
Cases cited: Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (No 3) [2018] FCA 2060; (2018) 138 IPR 242
Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 27
Date of hearing: 17 December 2024
Counsel for the Applicant: Ms J Beaumont SC and Ms G Rubagotti
Solicitor for the Applicant: Bird & Bird
Counsel for the Respondent: Mr A Fox SC and Mr A Smorchevsky
Solicitor for the Respondent: Griffith Hack Lawyers

ORDERS

NSD 698 of 2024
BETWEEN:

ABBEY LABORATORIES PTY LTD
(ACN 156 000 430)

Applicant

AND:

VIRBAC (AUSTRALIA) PTY LTD
(ACN 003 268 871)

Respondent

ORDER MADE BY:

JACKMAN J

DATE OF ORDER:

17 DECEMBER 2024

THE COURT ORDERS THAT:

1.The interlocutory application dated 10 December 2024 be dismissed.

2.Virbac pay Abbey’s costs of and incidental to the interlocutory application.

THE COURT NOTES THAT:

3.Abbey undertakes to Virbac and to the Court to keep a full account of all sales of Levamox Duo occurring in Australia from the date of these orders to the date of the final determination of this proceeding by recording the following information in respect of each sale:

(a)the customer name;

(b)the date of invoice;

(c)the quantity sold;

(d)the unit price including any rebates, incentives or other discounts; and

(e)Abbey’s profit and the manner of calculating the profit.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

REASONS FOR JUDGMENT
Delivered ex tempore, revised from transcript

JACKMAN J:

  1. The respondent in the proceedings (Virbac) is the patentee of Standard Patent No. 2012227241, entitled “Veterinary Topical Formulation” (Patent). It sells a product within the claims of the Patent called “Cydectin Platinum”. The applicant in the proceedings (Abbey) seeks orders for the revocation of the Patent. Virbac seeks remedies for infringement of the Patent if it is found to be valid. Abbey has recently launched a product called Levamox Duo. Virbac seeks an interlocutory injunction to restrain Abbey from, among other things, selling and marketing its product. The final hearing of the proceedings has been fixed to commence on 12 May 2025.

  2. There was considerable debate before me as to the principles applicable to whether there is a serious question to be tried…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCA 1488
Decision Date

CaseChat Overview and Summary

Abbey Laboratories Pty Ltd brought an interlocutory application for an injunction against Virbac (Australia) Pty Ltd, seeking to restrain Virbac from manufacturing, using, selling, or importing a generic version of Abbey’s patented product, Levamox Duo. The Federal Court of Australia was tasked with deciding whether to grant an injunction to Abbey, given that Virbac had recently launched a generic version of the product and argued that Abbey's patent was invalid.

The primary legal issues revolved around the balance of convenience and the detriment to both parties if an injunction were granted or denied. Abbey argued that the balance of convenience favoured the grant of an injunction, claiming that the detriment to them if the injunction was not granted was much more readily quantifiable in damages than the detriment to Virbac. Virbac, however, countered that Abbey had substantially delayed in bringing the proceedings and that their detriment would be significantly greater if an injunction were granted.

The court dismissed Abbey's application, finding that the balance of convenience did not favour the grant of an injunction. The court emphasised the substantial delay on the part of Abbey in bringing the proceedings and noted that the detriment to Virbac, should an injunction be granted, would be far more significant than any detriment Abbey would suffer if an injunction were not granted. The court also considered the availability of damages as an adequate remedy for Abbey if the patent were found to be invalid.

In light of the decision, the court ordered that the interlocutory application be dismissed and that Virbac pay Abbey’s costs of and incidental to the interlocutory application. Additionally, Abbey was required to keep a full account of all sales of Levamox Duo in Australia from the date of the orders until the final determination of the proceeding.

Orders

Orders of the court

1. The interlocutory application dated 10 December 2024 be dismissed.

2. Virbac pay Abbey’s costs of and incidental to the interlocutory application.

THE COURT NOTES THAT:

3. Abbey undertakes to Virbac and to the Court to keep a full account of all sales of Levamox Duo occurring in Australia from the date of these orders to the date of the final determination of this proceeding by recording the following information in respect of each sale:

(a) the customer name;

(b) the date of invoice;

(c) the quantity sold;

(d) the unit price including any rebates, incentives or other discounts; and

(e) Abbey’s profit and the manner of calculating the profit.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Abbey Laboratories Pty Ltd is the patent holder of a patent related to a veterinary medicine known as Levamox Duo. Virbac (Australia) Pty Ltd has recently launched a generic version of the same medicine. Abbey commenced proceedings against Virbac, alleging infringement of the patent. Abbey applied for an interlocutory injunction to restrain Virbac from selling the generic medicine. Abbey claims that if the injunction is not granted, it will suffer irreparable harm due to the loss of market share and potential damage to its reputation. Virbac argues that the patent is invalid and that the balance of convenience favours them, particularly because Abbey has substantially delayed in bringing this action. Virbac also submits that any detriment to Abbey would be more readily quantifiable in damages than any detriment to Virbac if the injunction is granted.

The matter came before the court on an application for an interlocutory injunction filed by Abbey Laboratories Pty Ltd on 10 December 2024. This was Abbey's attempt to prevent Virbac (Australia) Pty Ltd from selling its generic version of Levamox Duo. The application followed Virbac's launch of the generic medicine. The court heard submissions from both parties regarding the validity of the patent, the balance of convenience, and the potential harm to both parties if the injunction was granted or denied. This interlocutory application was the first step in what is expected to be a broader litigation process concerning the patent's validity and infringement.

Decision

Reasons for decision

Issues
1. Whether the balance of convenience favours the grant of an interlocutory injunction to Abbey Laboratories Pty Ltd.
2. Whether the substantial delay on the part of Abbey affects the balance of convenience.
3. Whether the detriment to Abbey if the injunction is not granted is more readily quantifiable in damages than the detriment to Virbac.

Held
1. The court concluded that the balance of convenience does not favour the grant of an interlocutory injunction to Abbey Laboratories Pty Ltd.
2. The substantial delay on the part of Abbey affects the balance of convenience against the grant of an injunction.
3. The detriment to Abbey if the injunction is not granted is more readily quantifiable in damages than the detriment to Virbac, but this factor was not decisive in the court's decision.

Ratio Decidendi

Legal Principle Established

The court considered the application for an interlocutory injunction by Abbey Laboratories Pty Ltd against Virbac (Australia) Pty Ltd, focusing on whether the balance of convenience favoured the grant of the injunction. The court recognised that the generic had recently launched its product and that Abbey was claiming for infringement of a patent that it alleged was invalid. The court examined the substantial delay by Abbey in bringing the application and the relative detriments to both parties if the injunction was not granted. The court applied the principles of equity, weighing the balance of convenience against the grant of an interlocutory injunction. In considering the substantial delay by Abbey, the court found that it was a significant factor affecting the balance of convenience. The court also noted that the quantifiable damages Abbey could claim were greater than those Virbac could incur if the injunction was not granted, but this did not tip the balance in Abbey's favour. The binding legal principle established in this case is that both the delay in bringing an application and the relative detriments to the parties are crucial factors in determining the balance of convenience. The court dismissed the application, reflecting its consideration of these factors in its final decision.